MA30991B1 - Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 - Google Patents
Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4Info
- Publication number
- MA30991B1 MA30991B1 MA31990A MA31990A MA30991B1 MA 30991 B1 MA30991 B1 MA 30991B1 MA 31990 A MA31990 A MA 31990A MA 31990 A MA31990 A MA 31990A MA 30991 B1 MA30991 B1 MA 30991B1
- Authority
- MA
- Morocco
- Prior art keywords
- agonists
- receptors
- benzamide derivatives
- compounds
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
CETTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU SON DÉRIVÉ PHARMACEUTIQUEMENT ACCEPTABLE, OÙ R1, R2, R3, R4, R5, M, N ET X SONT TELS QUE DÉFINIS DANS LE MÉMOIRE. L'INVENTION DÉCRIT ÉGALEMENT UN PROCÉDÉ PERMETTANT DE PRÉPARER DE TELS COMPOSÉS, UNE COMPOSITION PHARMACEUTIQUE COMPRENANT CES COMPOSÉS, AINSI QUE L'UTILISATION PHARMACOLOGIQUE DE CES COMPOSÉS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0625098A GB0625098D0 (en) | 2006-12-15 | 2006-12-15 | Novel compounds |
GB0715145A GB0715145D0 (en) | 2007-08-03 | 2007-08-03 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30991B1 true MA30991B1 (fr) | 2009-12-01 |
Family
ID=39149241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31990A MA30991B1 (fr) | 2006-12-15 | 2009-06-15 | Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 |
Country Status (21)
Country | Link |
---|---|
US (3) | US20080167377A1 (fr) |
EP (1) | EP2101751A1 (fr) |
JP (1) | JP5069752B2 (fr) |
KR (1) | KR20090089868A (fr) |
AR (1) | AR064361A1 (fr) |
AU (1) | AU2007331471C1 (fr) |
BR (1) | BRPI0720254A2 (fr) |
CA (1) | CA2672631A1 (fr) |
CL (1) | CL2007003640A1 (fr) |
CR (1) | CR10849A (fr) |
DO (1) | DOP2009000124A (fr) |
EA (1) | EA015931B1 (fr) |
IL (1) | IL198931A0 (fr) |
MA (1) | MA30991B1 (fr) |
MX (1) | MX2009006474A (fr) |
NO (1) | NO20092314L (fr) |
NZ (1) | NZ577109A (fr) |
PE (1) | PE20081579A1 (fr) |
SG (1) | SG177203A1 (fr) |
TW (1) | TW200848014A (fr) |
WO (1) | WO2008071736A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2172447A4 (fr) * | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | Composé amide |
GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
CA2707789A1 (fr) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation |
EP2565191B1 (fr) | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | Dérivés d'acide 4-(indol-7-ylcarbonylaminométhyl)cyclohexanecarboxylique comme antagonistes du récepteur EP4 utilisables pour le traitement de l'insuffisance rénale chronique ou de la néphropathie diabétique |
GB0810313D0 (en) * | 2008-06-05 | 2008-07-09 | Glaxo Group Ltd | Novel compounds |
GB0810617D0 (en) * | 2008-06-10 | 2008-07-16 | Glaxo Group Ltd | Novel pharmaceutical |
GB0810615D0 (en) * | 2008-06-10 | 2008-07-16 | Glaxo Group Ltd | Novel pharmaceutical |
ES2512727T3 (es) * | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
CN102596921B (zh) * | 2009-09-29 | 2015-04-29 | 葛兰素集团有限公司 | 新化合物 |
US20120190637A1 (en) | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
WO2012016109A2 (fr) * | 2010-07-30 | 2012-02-02 | Allergan, Inc. | Composés et procédés destinés à la réparation de la peau |
US8900571B2 (en) | 2010-08-19 | 2014-12-02 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8926963B2 (en) | 2010-08-19 | 2015-01-06 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8894992B2 (en) | 2010-08-19 | 2014-11-25 | Allergan, Inc. | Compositions and soft tissue replacement methods |
CN103097358B (zh) | 2010-09-21 | 2015-04-08 | 卫材R&D管理有限公司 | 药物组合物 |
US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
EP2814527A1 (fr) * | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions et procédés perfectionnés de remplacement de tissu mou |
EP2765128A1 (fr) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4 |
NZ717739A (en) | 2013-08-09 | 2023-12-22 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
NZ733234A (en) * | 2014-03-06 | 2018-08-31 | Aratana Therapeutics Inc | Crystalline forms of grapiprant |
EP3245186A1 (fr) | 2015-01-16 | 2017-11-22 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Procédé de préparation de composés phénoliques à partir de biomasse |
EP3184505A1 (fr) | 2015-12-22 | 2017-06-28 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Procédé de préparation de composés phénoliques à l'aide d'un catalyseur |
CN113905732A (zh) * | 2019-04-09 | 2022-01-07 | 纽罗比特科学有限公司 | 用于预防或治疗脊髓损伤或椎管狭窄的药物组合物 |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
CN111454150B (zh) * | 2019-12-25 | 2023-03-28 | 南京工业大学 | 一种(s)-2-芳基丙酸酯类化合物的合成方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
AUPO713297A0 (en) | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6586468B1 (en) | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
AUPP608898A0 (en) | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
WO2000021532A1 (fr) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Inhibition de la resorption osseuse |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0031315D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
SE0102300D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
EP1487437B1 (fr) | 2002-03-18 | 2006-08-16 | Pfizer Products Inc. | Utilisation d'agonistes selectifs du recepteur ep4 pour le traitement de maladies |
EP1499305A2 (fr) | 2002-04-12 | 2005-01-26 | Pfizer Japan Inc. | Utilisation de ligands du recepteur ep4 dans le traitement de maladies impliquant il-6 |
EP1556347A4 (fr) | 2002-06-10 | 2006-08-09 | Applied Research Systems | Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation |
AU2003275838A1 (en) | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
CA2511255C (fr) | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | Derives de 2-piperidone agonistes de la prostaglandine |
CN100408570C (zh) | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
EP1663979B1 (fr) | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2 |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
WO2005080367A1 (fr) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Agonistes des recepteurs ep2 |
CN1950333A (zh) | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
WO2005105733A1 (fr) * | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Composes aryl- ou heteroarylamides ortho-substitues |
WO2005116010A1 (fr) | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Agoniste du recepteur ep4, compositions et methodes associees ep4 receptor agonist, compositions and methods thereof |
ATE533766T1 (de) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
-
2007
- 2007-12-12 CA CA002672631A patent/CA2672631A1/fr not_active Abandoned
- 2007-12-12 MX MX2009006474A patent/MX2009006474A/es active IP Right Grant
- 2007-12-12 AU AU2007331471A patent/AU2007331471C1/en not_active Ceased
- 2007-12-12 US US11/954,815 patent/US20080167377A1/en not_active Abandoned
- 2007-12-12 JP JP2009540763A patent/JP5069752B2/ja not_active Expired - Fee Related
- 2007-12-12 BR BRPI0720254-7A patent/BRPI0720254A2/pt not_active IP Right Cessation
- 2007-12-12 NZ NZ577109A patent/NZ577109A/en not_active IP Right Cessation
- 2007-12-12 US US12/519,219 patent/US8314147B2/en not_active Expired - Fee Related
- 2007-12-12 SG SG2011091873A patent/SG177203A1/en unknown
- 2007-12-12 EP EP07857459A patent/EP2101751A1/fr not_active Withdrawn
- 2007-12-12 WO PCT/EP2007/063796 patent/WO2008071736A1/fr active Application Filing
- 2007-12-12 EA EA200970585A patent/EA015931B1/ru not_active IP Right Cessation
- 2007-12-12 KR KR1020097012174A patent/KR20090089868A/ko not_active Application Discontinuation
- 2007-12-13 PE PE2007001779A patent/PE20081579A1/es not_active Application Discontinuation
- 2007-12-13 TW TW096147555A patent/TW200848014A/zh unknown
- 2007-12-14 AR ARP070105631A patent/AR064361A1/es not_active Application Discontinuation
- 2007-12-14 CL CL200703640A patent/CL2007003640A1/es unknown
-
2009
- 2009-05-25 IL IL198931A patent/IL198931A0/en unknown
- 2009-05-29 DO DO2009000124A patent/DOP2009000124A/es unknown
- 2009-06-09 CR CR10849A patent/CR10849A/es unknown
- 2009-06-15 MA MA31990A patent/MA30991B1/fr unknown
- 2009-06-16 NO NO20092314A patent/NO20092314L/no not_active Application Discontinuation
-
2012
- 2012-10-08 US US13/646,949 patent/US20130261185A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DOP2009000124A (es) | 2010-03-31 |
TW200848014A (en) | 2008-12-16 |
US20130261185A1 (en) | 2013-10-03 |
NO20092314L (no) | 2009-08-31 |
US8314147B2 (en) | 2012-11-20 |
EA015931B1 (ru) | 2011-12-30 |
CA2672631A1 (fr) | 2008-06-19 |
JP2010513242A (ja) | 2010-04-30 |
SG177203A1 (en) | 2012-01-30 |
CR10849A (es) | 2009-08-12 |
MX2009006474A (es) | 2009-06-26 |
BRPI0720254A2 (pt) | 2014-01-07 |
US20100022650A1 (en) | 2010-01-28 |
US20080167377A1 (en) | 2008-07-10 |
WO2008071736A1 (fr) | 2008-06-19 |
CL2007003640A1 (es) | 2008-07-11 |
AU2007331471C1 (en) | 2013-07-25 |
IL198931A0 (en) | 2010-02-17 |
NZ577109A (en) | 2011-12-22 |
AR064361A1 (es) | 2009-04-01 |
AU2007331471A1 (en) | 2008-06-19 |
AU2007331471B2 (en) | 2013-01-10 |
JP5069752B2 (ja) | 2012-11-07 |
KR20090089868A (ko) | 2009-08-24 |
EP2101751A1 (fr) | 2009-09-23 |
EA200970585A1 (ru) | 2009-10-30 |
PE20081579A1 (es) | 2009-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30991B1 (fr) | Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 | |
MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
MA31988B1 (fr) | Derives d'aminopyrazole | |
MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
MA38325A3 (fr) | Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
MA32231B1 (fr) | Composés organiques | |
TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
MA30717B1 (fr) | Derives de pyridin-3-yle en tant qu'agents immunomodulateurs | |
MA30718B1 (fr) | Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MA29335B1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
MA32104B1 (fr) | Dérivés d'oxime en tant qu'inhibiteurs de hsp90 | |
MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
MA30284B1 (fr) | Composes de 8-azabicyclo[3.2.1]octane en tant qu'antagonistes du recepteur opioide mu | |
MA30166B1 (fr) | Imidazoles substitues et leur utilisation comme pesticides. | |
ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
MA33132B1 (fr) | Derives pyrazole utilises comme antagonistes du recepteur ccr4 | |
MA31699B1 (fr) | Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3 |